5'-tRNA半分子在透明细胞肾细胞癌中失调
研究前瞻性收集生物样本库中透明细胞肾细胞癌组织和血清,用TaqMan定量RT-PCR检测4种5'-tRNA半分子表达。结果显示所有5'-tRNA半分子在癌组织中下调,且与不良临床病理参数相关;部分在半分子在患者血清中水平低于对照,提示其作为诊断和预后生物标志物的潜力。
要点
- 所有研究的5'-tRNA半分子在透明细胞肾细胞癌组织中下调,提示潜在抑癌作用。
- 5'-tRNA-Lys-TTT半分子与ISUP分级呈负相关。
- 5'-tRNA-Arg-CCT、5'-tRNA-Glu-CTC和5'-tRNA-Lys-TTT在患者血清中水平低于对照。
核心结论
- 在透明细胞肾细胞癌患者中,5'-tRNA半分子有潜力作为诊断和预后生物标志物。
- 5'-tRNA半分子可能以抑癌方式发挥作用,这需要进一步研究确认。
研究设计与样本
- 前瞻性收集生物样本库中透明细胞肾细胞癌患者和非恶性疾病患者的组织和血清样本。
- 从95例透明细胞肾细胞癌和50例正常肾组织中分离总RNA,从27例透明细胞肾细胞癌患者和13例非恶性泌尿系统疾病患者血清中分离血清RNA。
- 对tRNA半分子3'端去磷酸化并连接适配体核苷酸,用基于TaqMan的定量逆转录聚合酶链反应检测4种5'-tRNA半分子表达。
主要发现
- 所有研究的5'-tRNA半分子在透明细胞肾细胞癌组织中下调,提示潜在抑癌作用。
- 在具有不良临床病理参数的患者中观察到5'-tRNA半分子表达降低。
- 所有5'-tRNA半分子在非器官局限的透明细胞肾细胞癌中表达水平较低。
- 5'-tRNA-Lys-TTT半分子与ISUP分级呈负相关。
- 透明细胞肾细胞癌患者中5'-tRNA-Arg-CCT、5'-tRNA-Glu-CTC和5'-tRNA-Lys-TTT半分子在血清中水平低于对照受试者,提示作为非侵入性生物标志物的相关性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 5'-tRNA半分子可能以抑癌方式发挥作用,这需要进一步研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In various malignancies RNA fragments are dysregulated. Our study was designed to determine the expression of 4, 5'-tRNA halves in the tissue and serum of patients with clear cell renal cell carcinoma. MATERIALS AND METHODS: Tissue and serum samples of patients with clear cell renal cell carcinoma and nonmalignant disease were collected prospectively in our biobank. We isolated total RNA from 95 clear cell renal cell carcinomas and 50 normal renal tissues as well as serum RNA from 27 patients with clear cell renal cell carcinoma and 13 with nonmalignant urological disease. To specifically determine the expression of 5'-tRNA halves we dephosphorylated and ligated an adaptor nucleotide to the 3' end of the tRNA halves. The expression levels of 4, 5'-tRNA halves (5'-tRNA-Arg-CCT, 5'-tRNA-Glu-CTC, 5'-tRNA-Leu-CAG and 5'-tRNA-Lys-TTT) were then measured by TaqMan® based quantitative reverse transcription-polymerase chain reaction. RESULTS: All studied 5'-tRNA halves were down-regulated in clear cell renal cell carcinoma tissues, indicating a potential role as a tumor suppressor. Furthermore, we noted decreased expression of 5'-tRNA halves in patients with adverse clinicopathological parameters. All 5'-tRNA halves were expressed at lower levels in nonorgan confined clear cell renal cell carcinoma. The 5'-tRNA-Lys-TTT halves inversely correlated with ISUP (International Society of Urological Pathology) grade. In patients with clear cell renal cell carcinoma 5'-tRNA-Arg-CCT, 5'-tRNA-Glu-CTC and 5'-tRNA-Lys-TTT halves circulated at lower levels than in control subjects, indicating relevance as noninvasive biomarkers. CONCLUSIONS: In patients with clear cell renal cell carcinoma 5'-tRNA halves have potential as diagnostic and prognostic biomarkers. The 5'-tRNA halves may act in a tumor suppressive manner, which requires further research to confirm.
引用
- Zhao C, Tolkach Y, Schmidt D, et al. 5'-tRNA Halves are Dysregulated in Clear Cell Renal Cell Carcinoma. J Urol. 2017. PMID: 28765068. doi:10.1016/j.juro.2017.07.082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。